Importantly, the spatial heterogeneity of PD‐L1 expression between primary and metastatic tumor is also reported in NSCLC and breast cancer,65, 66 in which evaluation of PD‐L1 expression is required for clinical use of PD‐1 inhibitors. This evidence concerns the gene CD274 and breast cancer.